Fluzone PF Quadrivalent 2022-2023 was administered by a healthcare professional. Proper preparation and injection technique were essential for its safe and effective delivery.

• Preparation: The vaccine was supplied as a clear and slightly opalescent suspension. Before administration, the prefilled syringe or vial should have been visually inspected for particulate matter or discoloration. If any abnormalities were present, the vaccine should not have been administered. The syringe or vial was gently shaken before use.
• Administration Route: The vaccine was administered intramuscularly only. Intravenous administration was contraindicated.
• Presentations: The vaccine was available in single-dose prefilled syringes (0.25 mL or 0.5 mL) or multi-dose vials (0.5 mL per dose).
• Annual Vaccination: Annual flu vaccination was consistently recommended because influenza viruses constantly evolve, and vaccine formulations are updated each year. This annual vaccination helps maintain optimal protection against the circulating strains.
• Post-Vaccination Monitoring: As with all injectable vaccines, recipients were often advised to remain at the vaccination site for 15 minutes after administration to monitor for immediate allergic reactions or vasovagal syncope (fainting).
• Storage: The vaccine needed to be stored refrigerated between 2° to 8°C (35° to 46°F) and should not have been frozen, as freezing could denature the antigens and render the vaccine ineffective.

Fluzone PF Quadrivalent 2022-2023 works by stimulating the body’s immune system to produce protective antibodies against the influenza viruses included in the vaccine.

• Antigen Delivery: The vaccine contained inactive (killed) influenza virus components, primarily the hemagglutinin (HA) protein, from the four selected strains. When injected into the muscle, these components are recognized by the immune system as foreign.
• Immune Response Generation: The immune system’s cells (e.g., B-cells and T-cells) identify these antigens. B-cells are activated to produce specific antibodies that can bind to and neutralize the influenza viruses. T-cells also become activated, contributing to a more robust cellular immune response.
• Antibody Development: It takes approximately two weeks after vaccination for the body to develop sufficient levels of protective antibodies. These antibodies circulate in the bloodstream, providing a defense mechanism.
• Protection Mechanism: If a vaccinated person is subsequently exposed to one of the influenza strains included in the vaccine, the pre-existing antibodies can rapidly recognize and attack the virus, helping to prevent infection or significantly reduce the severity of the illness and the risk of complications like pneumonia and hospitalization.
• Quadrivalent Advantage: By incorporating antigens from both B lineages in addition to the two A strains, the vaccine aimed to provide broader protection against the diverse influenza viruses circulating.

While Fluzone PF Quadrivalent 2022-2023 was generally well-tolerated, like all vaccines, it could cause side effects. Most were mild and temporary. Serious side effects were rare.

• Common Local Side Effects (at injection site):
  • Pain, tenderness, redness (erythema), swelling, or a hardened lump (induration). These were usually mild to moderate and resolved within a few days.
  • Bruising.
• Common Systemic Side Effects:
  • Headache.
  • Muscle aches (myalgia).
  • Feeling unwell (malaise) or fatigue.
  • Fever or chills (more common in younger children).
  • Nausea, vomiting, diarrhea, or loss of appetite (more common in younger children).
  • Irritability, fussiness, or abnormal crying (in infants and young children).
  • Drowsiness.
• Serious Side Effects (Rare):
  • Severe Allergic Reaction (Anaphylaxis): This is rare but can occur within minutes to hours of vaccination. Symptoms include hives, swelling of the face/throat, difficulty breathing, dizziness, or weakness. Medical supervision is crucial during and immediately after vaccination to manage such reactions.
  • Guillain-Barré Syndrome (GBS): GBS is a rare neurological disorder. While a causal link between GBS and seasonal influenza vaccines is inconclusive, if an excess risk exists, it is very small (e.g., about 1 additional case per million vaccinated persons). Individuals with a history of GBS within 6 weeks of a previous flu vaccination should discuss the risks and benefits with their doctor.
  • Syncope (Fainting): Can occur immediately after an injection, often as a psychogenic response to the needle.
  • Febrile Seizures: Seizures related to fever can occur, especially in young children prone to them.
  • Neurological disorders: Very rarely, conditions like encephalomyelitis, transverse myelitis, or brachial neuritis have been reported.
• Any persistent, severe, or unusual side effects should be reported to a healthcare provider.

Several important warnings and precautions were associated with the administration of Fluzone PF Quadrivalent 2022-2023 to ensure patient safety.

• Allergic Reactions: Do not administer to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine. Healthcare providers should have appropriate medical treatment readily available to manage severe allergic reactions.
• Guillain-Barré Syndrome (GBS): Individuals who have experienced GBS within 6 weeks following a previous influenza vaccination should have the decision to vaccinate based on careful consideration of potential benefits and risks.
• Altered Immunocompetence: Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a lower immune response to the vaccine, potentially leading to reduced protection.
• Acute Illness: Vaccination should be postponed in individuals with an acute illness accompanied by a moderate or high fever. A minor illness (e.g., common cold) without fever is usually not a reason to postpone vaccination.
• Limitations of Vaccine Effectiveness: No vaccine is 100% effective. Vaccination may not protect all recipients, particularly if the circulating strains do not closely match those in the vaccine or if the individual’s immune response is suboptimal.
• Egg Allergy: According to guidelines from public health authorities (including the CDC for the 2022-2023 season), persons with egg allergy of any severity could receive any licensed, recommended influenza vaccine that was otherwise appropriate for their age and health status. However, those with a history of severe allergic reaction to egg (e.g., angioedema, respiratory distress) should be vaccinated in a medical setting supervised by a healthcare provider able to manage severe allergic reactions.

•  Vaccines generally have limited drug-drug interactions. However:
  • Immunosuppressive Therapy: In individuals who are immunocompromised (e.g., due to certain diseases or medications like high-dose corticosteroids or chemotherapy), the immune response to the vaccine might be reduced, leading to less effective protection.
  • Co-administration with Other Vaccines: Fluzone PF Quadrivalent could generally be co-administered with other age-appropriate vaccines (e.g., COVID-19 vaccines) on the same day. However, it was important to use different injection sites. Healthcare providers always referred to current immunization schedules and guidelines for co-administration.

Fluzone PF Quadrivalent 2022-2023 was a prescription-only biological product (vaccine). It was administered by qualified healthcare professionals and was not available for self-administration.

• Medical Oversight: The administration of Fluzone PF Quadrivalent required oversight by a licensed healthcare provider (physician, nurse, pharmacist, etc.). This ensured proper screening, correct injection technique, and monitoring for any immediate adverse reactions.
• Not an OTC Product: Vaccines are not over-the-counter medications. Their administration is integrated into the healthcare system to ensure proper handling, cold chain management, administration by trained personnel, and comprehensive record-keeping.
• Public Health Programs: In many regions, influenza vaccination is a key component of public health initiatives, making it accessible through various channels such as doctor’s offices, clinics, pharmacies, and workplace vaccination programs.
• Record Keeping: Healthcare providers maintained detailed records of vaccination, including the vaccine type, lot number, administration date, and the identity of the person who administered it. This is vital for public health tracking, patient safety, and ensuring complete vaccination histories.
• Annual Recommendation: The recommendation for vaccination with specific influenza vaccine products was issued annually by public health authorities based on epidemiologic data and vaccine effectiveness studies for the upcoming flu season.

1. What is this vaccine used for? To prevent seasonal influenza in people aged 6 months and older.

2. What type of vaccine is it? Inactivated influenza virus vaccine (quadrivalent, preservative-free).

3. What strains are included in the 2022–2023 version? Two influenza A strains and two influenza B strains selected by WHO for that season.

4. What age group is it approved for? Individuals aged ≥6 months.

5. What is the dosage and route?

• 0.25 mL IM for ages 6–35 months

• 0.5 mL IM for ages ≥36 months.

6. Is it a live vaccine? No, it is an inactivated (non-live) vaccine.

7. What are common side effects? Injection site pain, fever, headache, muscle aches, and fatigue.

8. Can it cause serious reactions? Rarely—allergic reactions, Guillain-Barré syndrome, or febrile seizures in young children.

9. Is it safe during pregnancy? Yes, recommended during pregnancy to protect both mother and baby.

10. Is a prescription required? Yes, administered by healthcare professionals.

11. Is it available in Pakistan? Yes, through hospitals, immunization centers, and select pharmacies.

12. Can it be used with other vaccines? Yes, often co-administered with routine immunizations.

13. How long does protection last? Typically 6–12 months; annual vaccination is recommended.

14. What makes it different from Fluzone High-Dose? Lower antigen dose; intended for general population, not just seniors.

15. Is it used for COVID-19 prevention? No, it only protects against influenza.

16. Can it be used in immunocompromised patients? Yes, but consult a healthcare provider.

17. What should be avoided after vaccination? Monitor for allergic reactions; no specific activity restrictions.

18. Is it part of routine immunization? Yes, during flu season for eligible age groups.

19. What does “PF” mean? Preservative-free formulation.

20. Is a booster dose needed for children? Yes—children receiving flu vaccine for the first time need two doses at least 4 weeks apart